Constitutive and oxidative-stress-induced expression of VEGF in the RPE are differently regulated by different Mitogen-activated protein kinases

被引:58
作者
Klettner, Alexa [1 ]
Roider, Johann [1 ]
机构
[1] UKS H, Dept Ophthalmol, D-24105 Kiel, Germany
关键词
VEGF; Oxidative stress; MAPK; JNK; Erk; p38; ENDOTHELIAL GROWTH-FACTOR; PIGMENT EPITHELIAL-CELLS; MACULAR DEGENERATION; SELECTIVE-INHIBITION; DIABETIC-RETINOPATHY; BEVACIZUMAB AVASTIN; INDUCED APOPTOSIS; FACTOR GENE; HYPOXIA; ANGIOGENESIS;
D O I
10.1007/s00417-009-1139-x
中图分类号
R77 [眼科学];
学科分类号
100212 ;
摘要
Vascular endothelial growth factor (VEGF) is a fundamental factor for angiogenesis. It plays important roles in pathological conditions (e.g. the development of wet AMD), but also in the healthy organism) e.g. in maintaining the vasculature and supporting the retina). Recent therapies to treat the wet AMD focus on neutralizing VEGF indiscriminately. VEGF is constitutively expressed in the retina, but its expression is upregulated by various (noxious) stimuli, e.g. oxidative stress or hypoxia. Discrimination between constitutive expression of VEGF and its pathological upregulation might provide the possibility of focusing on inhibiting the pathological expression only. Here, we focused on the influence of different mitogen-activated protein kinase (MAPK) (p38, Erk, JNK) on the secretion and expression of VEGF, with or without being challenged by oxidative stress. VEGF secretion was measured using a perfusion organ culture model; expression was examined in primary RPE culture and Western blotting. Constitutive VEGF expression and secretion can be diminished by inhibiting p38, while inhibiting Erk or JNK does not show a significant effect. When challenged with oxidative stress (250 A mu M t-butylhydroperoxide), VEGF expression and secretion increases and the influence of the MAPK changes: While p38 still accounts for about 30% of the secretion, Erk shows a similar influence. Inhibiting JNK presents conflicting results. In organ culture, inhibiting JNK significantly increases VEGF secretion after stimulation with 250 A mu M tBH, while with regard to VEGF expression in RPE cell culture, this effect could not be seen. Constitutive and oxidative stress induced VEGF secretion, and expression is differently regulated, which might offer an opportunity to selectively inhibit pathological VEGF expression only.
引用
收藏
页码:1487 / 1492
页数:6
相关论文
共 36 条
[1]   Intravitreal bevacizumab (Avastin) for neovascular age-related macular degeneration [J].
Avery, RL ;
Pieramici, DJ ;
Rabena, MD ;
Castellarin, AA ;
Nasir, MA ;
Giust, MJ .
OPHTHALMOLOGY, 2006, 113 (03) :363-372
[2]   MAP kinases and hypoxia in the control of VEGF expression [J].
Berra, E ;
Pagès, G ;
Pouysségur, J .
CANCER AND METASTASIS REVIEWS, 2000, 19 (1-2) :139-145
[3]   Thrombin-induced VEGF expression in human retinal pigment epithelial cells [J].
Bian, Zong-Mei ;
Elner, Susan G. ;
Elner, Victor M. .
INVESTIGATIVE OPHTHALMOLOGY & VISUAL SCIENCE, 2007, 48 (06) :2738-2746
[4]   Regulation of VEGF mRNA expression and protein secretion by TGF-β2 in human retinal pigment epithelial cells [J].
Bian, Zong-Mei ;
Elner, Susan G. ;
Elner, Victor M. .
EXPERIMENTAL EYE RESEARCH, 2007, 84 (05) :812-822
[5]   Reactive oxygen species activate the HIF-1α promoter via a functional NFκB site [J].
Bonello, Steve ;
Zahringer, Christian ;
BelAiba, Rachida S. ;
Djordjevic, Talija ;
Hess, John ;
Michiels, Carine ;
Kietzmann, Thomas ;
Goerlach, Agnes .
ARTERIOSCLEROSIS THROMBOSIS AND VASCULAR BIOLOGY, 2007, 27 (04) :755-761
[6]   Vascular endothelial growth factor and diabetic retinopathy: Role of oxidative stress [J].
Caldwell, RB ;
Bartoli, M ;
Behzadian, MA ;
El-Remessy, AEB ;
Al-Shabrawey, M ;
Platt, DH ;
Liou, GI ;
Caldwell, RW .
CURRENT DRUG TARGETS, 2005, 6 (04) :511-524
[7]   RETRACTED: Oxidative stress inactivates VEGF survival signaling in retinal endothelial cells via PI 3-kinase tyrosine nitration(Retracted article.See vol.129,2016) [J].
El-Remessy, AB ;
Bartoli, M ;
Platt, DH ;
Fulton, D ;
Caldwell, RB .
JOURNAL OF CELL SCIENCE, 2005, 118 (01) :243-252
[8]  
Fan Bei, 2005, Shengli Xuebao, V57, P13
[9]   Looking beyond Lucentis on the management of macular degeneration [J].
Fletcher, E. C. ;
Chong, N. V. .
EYE, 2008, 22 (06) :742-750
[10]  
Forsythe JA, 1996, MOL CELL BIOL, V16, P4604